Oncology Developer Yahong Bags China’s First Biotech IPO Of 2022

Active Funding Ahead Of Lunar New Year

fund raising
VC/PE funds continued pumping fresh funds into Chinese biotechs despite sluggish performance of publicly traded companies • Source: Alamy

More from China

More from Focus On Asia